Porakishvili, Nina - University of Westminster - Department of Biomedical Sciences

个人简介

I am a Principal Lecturer in the Department of Biomedical Sciences of the Faculty of Science and Technology. I lead three modules 3BLY511 - BSc Molecular Genetics; 3BLY615 - BSc Molecular Therapeutics and 3BIO7P5 - MSc Immunopathology. I am Faculty academic coordinator of ERASMUS PLUS program.Currently I act as: Coordinator of the EU project TEMPUS-JPCR-544282 "The development of a curriculum and establishment of a regional training platform for haematology in life sciences and medicine". Coordinator of the EU project TEMPUS-JPHES-543802 "Establishment of Multidisciplinary Innovative Centres for the Development of Virtual Laboratories (MICVL) in Biology and Medicine". Coordinator of the EU project TEMPUS-JPCR-158627 "Development of the e-learning and distance learning courses and assessment in Biomedical Sciences in Southern Caucasus". In 2011 this project was announced as the best regional TEMPUS project during 20 years of the program existence and in November, 2012 it won Times Higher Education (THE) award as UK International Collaboration of the Year. Qualifications I have completed by secondary education in Tbilisi, Georgia, with the golden medal, as the top 1% of the graduates and studied Biology (BSc) and Genetics (MSc) at Tbilisi State University, Georgia, and graduated in with the First Class degree as the top 5% of the year. I continued my PhD studies in Immunology in Lomonossov Moscow State University, Russia, and have been awarded PhD degree in Immunology. At the age of 32 I have been awarded a title of the Professor of Immunology at Tbilisi State University, Georgia, and was the youngest woman professor in the country.

研究领域

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

I was the first to demonstrate heterogeneity of the expression of the toll-like receptor CD180/RP105 on Chronic Lymphocytic Leukaemia (CLL) cells in correlation with B cell receptor (BCR) that may represent a novel prognostic marker (Porakishvili et al., 2005). I have further demonstrated that CD180 and BCR use the same signalling pathways downstream from ZAP70/Syk to Akt that increases survival of CLL cells (Porakishvili et al., 2011). Very recently (Porakishvili et al., paper under submission) I showed that engagement of CD180 can switch BCR signalling from pro-survival Btk/PI3K/Akt pathway to pro-apoptotic p38MAPK pathway that would represent an interest as a therapeutic target. I have demonstrated expansion of CD4+ perforin (PF) and granzyme expressing cytotoxic lymphocytes (CTLs) in patients with CLL. CD4+PF+ T cells were able to induce PF-mediated apoptosis in vitro of the autologous leukaemic cells in presence of bispecific CD19xCD3 antibodies (Porakishvili et al., 2001,2004). My research group further showed that CD4+PF+ CTLs in CLL are involved in anti-cytomegaloviral responses and belong to effector memory T cells (Walton et al., 2010). With the colleagues from the Brest University (France) I demonstrated induction of apoptosis of B-CLL cells by CD5 ligation, dependent on the level of the expression of CD79b and CD38 cells (Pers et al., 2002). The apoptosis is accompanied by the decrease in Bcl2/Bax ratio. Recently we have shown co-function of surface IgM and CD5 in pro-apoptotic signalling in B-CLL cells (Nedellec et al., 2005). I have been working on the construction of epitope-specific contraceptive and anti-tumour vaccine and demonstrated that the mutant -subunit of human chorionic gonadotropin (hCG) with a single amino-acid substitution 68 ArgGlu had a decreased cross-reactivity with the -chain of human luteinising hormone while retaining immunogenicity of the hCG-specific epitopes. In mutant protein the dominant antibody response was re-directed towards the C-terminal peptide (CTP). Recently we demonstrated that auto-antibodies to hCG prevent malignisation of benign tumour (Chikadze et al., 2010). We have now optimised vaccine prototype for hCG including career molecule and adjuvant (Chikadze et al, paper in preparation). Current research interests The function of CD180 and on CD180/BCR-mediated pro-survival and pro-apoptotic signalling in B cells and in CLL cells as a translational study for the development of new immunotherapeutic approaches for the treatment of CLL; Further development of hCG-based anti-tumour vaccine prototype. My research collaborators include leading experts in the field of CLL and hCG from the US, Italy, France and UK.